Media headlines about Kindred Biosciences (NASDAQ:KIN) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kindred Biosciences earned a news impact score of 0.15 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.5042508315095 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Kindred Biosciences (NASDAQ:KIN) opened at 7.75 on Thursday. The stock’s market capitalization is $180.65 million. Kindred Biosciences has a 12-month low of $3.83 and a 12-month high of $9.65. The company has a 50-day moving average price of $7.68 and a 200-day moving average price of $6.84.
Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.04. On average, equities research analysts forecast that Kindred Biosciences will post ($1.40) earnings per share for the current year.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a research note on Tuesday, June 20th. Aegis began coverage on Kindred Biosciences in a report on Friday, June 16th. They issued a “buy” rating and a $10.50 target price for the company. ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. FBR & Co reiterated a “buy” rating on shares of Kindred Biosciences in a report on Wednesday, May 31st. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $8.00 target price on shares of Kindred Biosciences in a report on Monday, May 15th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $8.80.
In other Kindred Biosciences news, insider Richard Chin sold 13,000 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $7.75, for a total value of $100,750.00. Following the completion of the transaction, the insider now directly owns 2,310,546 shares of the company’s stock, valued at approximately $17,906,731.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Park West Asset Management Llc acquired 15,311 shares of the firm’s stock in a transaction on Thursday, June 8th. The stock was purchased at an average cost of $6.65 per share, with a total value of $101,818.15. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 770,387 shares of company stock valued at $5,660,987. 19.10% of the stock is owned by insiders.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with our FREE daily email newsletter.